Aura Biosciences, Inc. (AURA): who owns it and who trades it
As of Nov 16, 2026, AURA insiders reported 12 open-market sales worth $40M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Matrix Capital Management Company, LP (10% owner), with $39M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Aura Biosciences
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns AURA
146 funds and institutions reported AURA shares worth $699M at the end of Q2 2026, about 95% of the company. The largest holder is TCG Crossover Management, LLC with 9.2%.
Funds and institutions (13F) 95%Everyone else 5%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| TCG Crossover Management, LLC | 9.53M | 9.16% | $67.7M | – |
| Montanova Capital, LLC | 7.21M | 6.92% | $51.2M | +65% |
| Frazier Life Sciences Management, L.P. | 7.10M | 6.82% | $50.4M | +39% |
| Nantahala Capital Management, LLC | 5.90M | 5.67% | $41.9M | +179% |
| Long Focus Capital Management, LLC | 5.12M | 4.92% | $36.3M | +11% |
| BlackRock, Inc. | 4.71M | 4.52% | $33.4M | +31% |
| Adage Capital Partners Gp, L.l.c. | 4.64M | 4.46% | $32.9M | -5% |
| Caligan Partners LP | 4.30M | 4.13% | $30.5M | +1770% |
| Vanguard Capital Management LLC | 4.10M | 3.94% | $29.1M | +83% |
| Fcpm III Services B.v. | 4.05M | 3.90% | $28.8M | – |
| Orbimed Advisors LLC | 3.33M | 3.20% | $23.7M | – |
| Medicxi Ventures Management (Jersey) Ltd | 3.04M | 2.92% | $21.6M | No change |
| Jupiter Topco LLC | 2.50M | 2.40% | $17.8M | – |
| Ra Capital Management, L.P. | 2.50M | 2.40% | $17.8M | – |
| Balyasny Asset Management L.P. | 2.35M | 2.26% | $16.7M | +322% |
| Franklin Resources Inc | 2.07M | 1.99% | $14.7M | No change |
| Geode Capital Management, LLC | 1.75M | 1.69% | $12.5M | +34% |
| Redmile Group, LLC | 1.67M | 1.60% | $11.8M | – |
| EcoR1 Capital, LLC | 1.67M | 1.60% | $11.8M | – |
| Trails Edge Capital Partners, LP | 1.44M | 1.39% | $10.2M | – |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, AURA insiders reported $0 of open-market purchases and $40M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 16, 2026 | Janet Jill Hopkins | Chief Medical Officer | Sale | 16,903 | $7.05 | $119K | Form 4 |
| Jun 16, 2026 | Anthony S Gibney | See Remarks | Sale | 12,824 | $6.42 | $82.3K | Form 4 |
| May 7, 2026 | Matrix Capital Management Company, LP +1 | 10% owner | Sale | 6.92M | $5.64 | $39M | Form 4 |
| Apr 16, 2026 | Conor Kilroy | See Remarks | Sale | 11,738 | $7.02 | $82.4K | Form 4 |
| Feb 17, 2026 | Conor Kilroy | See Remarks | Sale | 12,079 | $5.05 | $61K | Form 4 |
| Feb 17, 2026 | Mark Plavsic | Chief Technology Officer | Sale | 15,890 | $5.05 | $80.2K | Form 4 |
| Feb 17, 2026 | Janet Jill Hopkins | Chief Medical Officer | Sale | 20,401 | $5.06 | $103K | Form 4 |
| Feb 17, 2026 | Amy Elazzouzi | Vice president | Sale | 8,549 | $5.06 | $43.3K | Form 4 |
| Feb 17, 2026 | los Pinos Elisabet de | Director | Sale | 47,648 | $5.06 | $241K | Form 4 |
| Jan 20, 2026 | Amy Elazzouzi | Vice president | Sale | 1,581 | $4.86 | $7.7K | Form 4 |
| Jan 20, 2026 | los Pinos Elisabet de | Director | Sale | 16,928 | $4.86 | $82.3K | Form 4 |
| Nov 17, 2025 | Janet Jill Hopkins | Chief Medical Officer | Sale | 17,109 | $5.42 | $92.7K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Matrix Capital Management Company, LP | 10% owner | – | $39M | May 7, 2026 |
| los Pinos Elisabet de | See Remarks, Director | – | $323K | Feb 17, 2026 |
| Janet Jill Hopkins | Chief Medical Officer | – | $315K | Nov 16, 2026 |
| Conor Kilroy | See Remarks | – | $143K | Apr 16, 2026 |
| Anthony S Gibney | See Remarks | – | $82.3K | Jun 16, 2026 |
| Mark Plavsic | Chief Technology Officer | – | $80.2K | Feb 17, 2026 |
| Amy Elazzouzi | Senior Vice President, Finance | – | $50.9K | Feb 17, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
AURA short interest
High short interest. 10.1% of AURA shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went up 232%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 10.46M AURA shares were sold short, 10.1% of the shares outstanding, down 3.9% from the report before. At the average daily volume of 765,417 shares, buying them all back would take about 13.7 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 10.46M | 10.09% | -4% | 765,417 | 13.7 |
| Oct 15, 2026 | 10.89M | 10.50% | +5% | 1.02M | 10.6 |
| Sep 30, 2026 | 10.37M | 10.00% | +47% | 1.12M | 9.2 |
| Sep 15, 2026 | 7.05M | 6.80% | +14% | 604,730 | 11.7 |
| Aug 31, 2026 | 6.20M | 5.98% | +1% | 972,230 | 6.4 |
| Aug 14, 2026 | 6.16M | 5.94% | -3% | 622,079 | 9.9 |
| Jul 31, 2026 | 6.36M | 9.91% | +13% | 344,394 | 18.5 |
| Jul 15, 2026 | 5.61M | 8.74% | -19% | 692,744 | 8.1 |
| Jun 30, 2026 | 6.93M | 10.81% | +29% | 742,197 | 9.3 |
| Jun 15, 2026 | 5.39M | 8.40% | +43% | 521,877 | 10.3 |
| May 29, 2026 | 3.76M | 5.87% | +19% | 496,436 | 7.6 |
| May 15, 2026 | 3.16M | 4.92% | +44% | 1.13M | 2.8 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Aura Biosciences company events
Aura Biosciences filed 10 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 9, 2026.
- Nov 9, 2026AnnouncementThe Company updated its corporate presentation for use in meetings with investors, analysts, and others. Filing
- Aug 11, 2026LeadershipThe Board appointed Susan Abu-Absi, Ph.D., age 52, as the Company’s Chief Operating Officer, effective as of August 10, 2026. Filing
- Aug 5, 2026VoteReported shareholder vote results. Filing
- Jul 8, 2026LeadershipThe Board of Directors of Aura Biosciences, Inc. increased the size of the Board from six to seven directors and unanimously appointed Jeremy Bender, Ph.D., M.B.A., as a Class II director, effective July 7, 2026, to fill the newly created vacancy. Filing
- Jun 11, 2026VoteReported shareholder vote results. Filing
- May 11, 2026AnnouncementThe Company updated its corporate presentation for use in meetings with investors, analysts, and others. Filing
- May 5, 2026AgreementAura Biosciences, Inc. entered into an underwriting agreement with Leerink Partners LLC, TD Securities (USA) LLC and Evercore Group L.L.C., as representatives of the several underwriters named therein, relating to an underwritten public offering (including the offering of the Option Shares (as… Filing
- May 4, 2026AgreementAura Biosciences, Inc. and Matrix Capital Management Master Fund, LP entered into a stock purchase agreement pursuant to which the Company has agreed to repurchase, in a privately negotiated transaction, up to 6,922,870 shares of its common stock, which the Company believes represents all shares of… Filing
- May 4, 2026LeadershipThe Board of Directors of Aura Biosciences, Inc. appointed Natalie Holles as the Company’s Chief Executive Officer and President and as a Class I director with a term expiring at the Company’s 2028 annual meeting of stockholders, effective as of April 30, 2026. Filing
- Mar 30, 2026AnnouncementThe Company updated its corporate presentation for use in meetings with investors, analysts, and others. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Aura Biosciences financials
Famous investors that hold AURA
4 of the 50 well-known investors we track reported holding AURA in their latest 13F filing. The largest position is Ken Griffin's, worth $1.9M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 304,523 | $1.9M | 0.0% | +487% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 164,651 | $1M | 0.0% | +822% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 140,084 | $880K | 0.0% | -20% |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 83,508 | $524K | 0.0% | No change |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 10 filings named AURA in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | ADAR1 Capital Management, LLC | 13G | 5.2% |
| Nov 16, 2026 | ADAR1 Capital Management, LLC | 13G | 5.2% |
| Nov 16, 2026 | TCG Crossover GP II, LLC | 13G/A | 5.0% |
| Nov 16, 2026 | TCG Crossover GP II, LLC | 13G/A | 5.0% |
| Nov 13, 2026 | Montanova Capital, LLC | 13G/A | 2.9% |
| Nov 13, 2026 | Montanova Capital, LLC | 13G/A | 2.9% |
| Oct 27, 2026 | BlackRock, Inc. | 13G | 5.0% |
| Oct 27, 2026 | BlackRock, Inc. | 13G | 5.0% |
| Oct 1, 2026 | ForGrowth III PA B.V. | 13G | 5.1% |
| Oct 1, 2026 | ForGrowth III PA B.V. | 13G | 5.1% |
Questions about Aura Biosciences, Inc. (AURA) stock
Who owns the most AURA stock?
The largest reported owner of Aura Biosciences, Inc. (AURA) is TCG Crossover Management, LLC, with 9.2% of the company. In total, 146 funds and institutions reported holding AURA at the end of Q2 2026, together about 95% of the shares. See the largest owners.
Are AURA insiders buying or selling?
In the last 12 months, AURA insiders reported no open-market purchases and 12 sales worth $40M. The latest trade was on Nov 16, 2026. See every trade.
What is the short interest in AURA?
As of Oct 30, 2026, 10.46M AURA shares were sold short, 10.1% of the shares outstanding, down 3.9% from the report before. At the average daily volume of 765,417 shares, buying them all back would take about 13.7 trading days (days to cover). See the history.
Which famous investors hold AURA?
4 of the 50 well-known investors we track reported AURA in their latest 13F filing, including Ken Griffin, Steve Cohen, Jim Simons. The largest position is worth $1.9M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.